The long-term effects of rosiglitazone on serum lipid concentrations and body weight

Wan Sub Shim, Mi Young Do, Soo Kyung Kim, Hae Jin Kim, Kyu Yeon Hur, Eun Seok Kang, Chul Woo Ahn, Sung Kil Lim, Hyun Chul Lee, Bong Soo Cha

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.

Original languageEnglish
Pages (from-to)453-459
Number of pages7
JournalClinical Endocrinology
Volume65
Issue number4
DOIs
Publication statusPublished - 2006 Oct 1

Fingerprint

rosiglitazone
HDL Cholesterol
LDL Lipoproteins
Body Weight
Lipids
Serum
Cholesterol
Particle Size
LDL Cholesterol
Fasting
Hemoglobins
Insulin

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Shim, W. S., Do, M. Y., Kim, S. K., Kim, H. J., Hur, K. Y., Kang, E. S., ... Cha, B. S. (2006). The long-term effects of rosiglitazone on serum lipid concentrations and body weight. Clinical Endocrinology, 65(4), 453-459. https://doi.org/10.1111/j.1365-2265.2006.02614.x
Shim, Wan Sub ; Do, Mi Young ; Kim, Soo Kyung ; Kim, Hae Jin ; Hur, Kyu Yeon ; Kang, Eun Seok ; Ahn, Chul Woo ; Lim, Sung Kil ; Lee, Hyun Chul ; Cha, Bong Soo. / The long-term effects of rosiglitazone on serum lipid concentrations and body weight. In: Clinical Endocrinology. 2006 ; Vol. 65, No. 4. pp. 453-459.
@article{28974f9c194941449a89d97e6c9ecba9,
title = "The long-term effects of rosiglitazone on serum lipid concentrations and body weight",
abstract = "Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.",
author = "Shim, {Wan Sub} and Do, {Mi Young} and Kim, {Soo Kyung} and Kim, {Hae Jin} and Hur, {Kyu Yeon} and Kang, {Eun Seok} and Ahn, {Chul Woo} and Lim, {Sung Kil} and Lee, {Hyun Chul} and Cha, {Bong Soo}",
year = "2006",
month = "10",
day = "1",
doi = "10.1111/j.1365-2265.2006.02614.x",
language = "English",
volume = "65",
pages = "453--459",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "4",

}

Shim, WS, Do, MY, Kim, SK, Kim, HJ, Hur, KY, Kang, ES, Ahn, CW, Lim, SK, Lee, HC & Cha, BS 2006, 'The long-term effects of rosiglitazone on serum lipid concentrations and body weight', Clinical Endocrinology, vol. 65, no. 4, pp. 453-459. https://doi.org/10.1111/j.1365-2265.2006.02614.x

The long-term effects of rosiglitazone on serum lipid concentrations and body weight. / Shim, Wan Sub; Do, Mi Young; Kim, Soo Kyung; Kim, Hae Jin; Hur, Kyu Yeon; Kang, Eun Seok; Ahn, Chul Woo; Lim, Sung Kil; Lee, Hyun Chul; Cha, Bong Soo.

In: Clinical Endocrinology, Vol. 65, No. 4, 01.10.2006, p. 453-459.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The long-term effects of rosiglitazone on serum lipid concentrations and body weight

AU - Shim, Wan Sub

AU - Do, Mi Young

AU - Kim, Soo Kyung

AU - Kim, Hae Jin

AU - Hur, Kyu Yeon

AU - Kang, Eun Seok

AU - Ahn, Chul Woo

AU - Lim, Sung Kil

AU - Lee, Hyun Chul

AU - Cha, Bong Soo

PY - 2006/10/1

Y1 - 2006/10/1

N2 - Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.

AB - Objective: Although rosiglitazone, an insulin sensitizer, is known to have beneficial effects on high density lipoprotein cholesterol (HDL-C) concentrations and low density lipoprotein (LDL) particle size, it has unwanted effects on total cholesterol (TC) and LDL cholesterol (LDL-C) concentrations and body weight in some short-term studies. The aim of this study was to evaluate the long-term effects of rosiglitazone on serum lipid levels and body weight. Design: Open labelled clinical study. Patients and measurements: We prospectively evaluated fasting serum glucose, haemoglobin A1c (HbA1c), lipid profiles and body weight at baseline and every 3 months after the use of rosiglitazone (4 mg/day) for 18 months in 202 type 2 diabetic patients. Results: TC levels increased maximally at 3 months and decreased thereafter. However, overall, TC levels remained significantly higher at 18 months than those at baseline. LDL-C levels from the 3-month to the 12-month timepoint were significantly higher than those at baseline. However, after 15 months, LDL-C concentrations were not significantly different from basal LDL-C concentrations. HDL-C levels increased after the first 3 months and these levels were maintained. The increment of change in HDL-C was more prominent in patients with low basal HDL-C concentrations than in patients with high basal HDL-C concentrations. Body weight increased after the first 3 months and these levels were maintained. Conclusions: HDL-C and body weight increased and remained elevated for the duration of the study. There was an initial increase in LDL-C but this attenuated and by the end of the study was not significantly elevated above baseline levels.

UR - http://www.scopus.com/inward/record.url?scp=33748767108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748767108&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2265.2006.02614.x

DO - 10.1111/j.1365-2265.2006.02614.x

M3 - Article

C2 - 16984237

AN - SCOPUS:33748767108

VL - 65

SP - 453

EP - 459

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 4

ER -